A risk-benefit assessment of drugs used in the management of glaucoma.
All antiglaucoma drugs are able to lower intraocular pressure (IOP) to variable degrees. However, all of them can possibly produce ocular and/or systemic adverse effects, some of which are not acceptable. Therefore, the drug or the combination of drugs which is efficacious enough to achieve the target IOP and have no or negligible adverse effects should be identified for each glaucoma patient, considering their ocular (e.g. the stage of glaucomatous damage, refraction) and systemic (e.g. age, cardiovascular disease) conditions.
Taniguchi
T
T
Department of Ophthalmology, Gifu University School of Medicine, Japan.
Kitazawa
Y
Y
D000322:Adrenergic Agonists / Q000009:adverse effects / Q000627:therapeutic use; D002217:Carbachol / Q000009:adverse effects / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D010862:Pilocarpine / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D000322:Adrenergic Agonists; D002257:Carbonic Anhydrase Inhibitors; D010862:Pilocarpine; D002217:Carbachol